A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT05573464 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

559

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: BGF MDI HFO 320/14.4/9.6 μg
DRUG: BGF MDI HFA 320/14.4/9.6 μg

Sponsor

AstraZeneca